Skip to main content
Gulf Pharmaceutical Industries logo

Gulf Pharmaceutical Industries — Investor Relations & Filings

Ticker · JULPHAR ISIN · AEG000201018 Abu Dhabi Securities Exchange Manufacturing
Open in API
Filings indexed 360 across all filing types
Latest filing 2021-09-04 Capital/Financing Update
Country AE United Arab Emirates
Listing Abu Dhabi Securities Exchange JULPHAR

About Gulf Pharmaceutical Industries

https://www.Julphar.net

Gulf Pharmaceutical Industries (Julphar) is a prominent pharmaceutical manufacturer and distributor. The company specializes in producing a diverse portfolio of medicines, vaccines, and consumer healthcare products, addressing a broad spectrum of health conditions. Julphar is recognized as one of the largest generic pharmaceutical manufacturers in the Middle East and North Africa, and a leading global producer of insulin. Utilizing internationally accredited, state-of-the-art facilities, it manufactures over one million medicine boxes daily, distributing products to more than 40 countries. The company's operations emphasize high quality and safety standards in its comprehensive manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Gulf Pharmaceutical Industries ‘Julphar’ divests 100% shareholding in Gulf Inject LLC
Capital/Financing Update Classification · 95% confidence The document is a short disclosure form dated 05-September-2021 from Gulf Pharmaceutical Industries P.S.C. It announces the sale of 100% ownership in Gulf Inject LLC, describing the expected financial impact on Q3 2021 results. The document is brief (1704 characters) and serves as a material information disclosure rather than a detailed financial report or analysis. It does not contain financial statements or detailed financial data, nor is it a certification or voting result. It is an announcement of a material transaction affecting the company's financial position. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as divestitures.
2021-09-04 English
شركة الخليج للصناعات الدوائية بيانات صحفية عامة
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the sale of a subsidiary company, Gulf Inject, by Julphar (Gulf Pharmaceutical Industries). It discusses the strategic rationale behind the sale, the business focus, and quotes from company executives. There are no financial statements, detailed financial performance data, or regulatory form references. The document is relatively short (3432 characters) and serves as a corporate announcement about a transaction rather than a full financial report or regulatory filing. This fits best under Capital/Financing Update (CAP) as it relates to a significant financing/asset sale transaction by the company.
2021-09-04 Arabic
Gulf Pharmaceutical Industries General Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the divestment of a subsidiary company by Gulf Pharmaceutical Industries (Julphar). It details the sale of Gulf Inject LLC to another company, explaining the strategic rationale behind the transaction. There are no financial statements, regulatory certifications, or detailed financial data presented. The document is not an earnings release, annual report, or any form of regulatory filing. It is a corporate announcement about a capital transaction (divestment) which fits best under Capital/Financing Update (CAP). The document length is 3554 characters, which is consistent with a press release rather than a full report.
2021-09-04 English
JULPHAR Resumption
Regulatory Filings
2021-08-15 Arabic
JULPHAR Resumption
Regulatory Filings
2021-08-15 English
شركة الخليج للصناعات الدوائية بيان صحفي عن النتائج المالية للفترة المنتهية في 30 يونيو,2021
Interim / Quarterly Report Classification · 95% confidence The document is a press release announcing the financial results of Julphar for the second quarter of 2021. It includes specific financial figures such as net profit, revenue growth, and operational highlights for the quarter ended June 30, 2021. The text focuses on quarterly financial performance and business updates rather than a full annual report or detailed interim report. The document length is 4182 characters, which is relatively short but contains substantive financial data and analysis for the quarter. Therefore, it fits the definition of an Interim / Quarterly Report (IR) rather than a brief earnings release or a report publication announcement. Q2 2021
2021-08-14 Arabic

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.